Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 583-588, October 2004

Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen:☆☆☆☆☆

Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

  • Christina Davies, MSc MB ChB (Epidemiology)

      Affiliations

    • Corresponding Author InformationTel.: +44-1865-404840; fax: +44-1865-40484551
    • Dr Davies is the international coordinator of the ATLAS study, and is involved in the central coordination of the EBCTCG.

Clinical Trial Service and Epidemiological Studies Unit, Radcliffe Infirmary, University of Oxford, Oxford OX2 6HE, UK

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Pfizer.

☆ For Correspondence: R. Charles Coombes, Department of Cancer Medicine, Imperial College and Charing Cross Hospital, London, UK.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(04)00121-5

doi:10.1016/j.ctrv.2004.06.005

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 583-588, October 2004

Article Tools